Stock GSK GSK PLC
Add to a list

ETFs GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E.
Other stock markets
 16:35:13 11/03/2026 GMT 		5-day change 1st Jan Change
2,066.00 GBX +0.10% Intraday chart for GSK plc -2.64% +13.24%
03-11 GSK plc Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 11:30 AM
03-11 FTSE 100 in the Red as US-Iran War Escalates; UK Commits to IEA Oil Stockpile Release MT

ETFs positioned on GSK plc

Name Varia. Jan 1. Weight AuM
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY ETF Nomura NEXT FUNDS International Equity MSCI-KOKUSAI (Yen-Hedged) ETF - JPY
-1.55%3.15% 26 M€
SYGNIA ITRIX FTSE 100 ETF ETF Sygnia Itrix FTSE 100 ETF
+1.51%2.97% 64 M€
FIRST TRUST INTERNATIONAL CAPITAL STRENGTH ETF - CAD ETF First Trust International Capital Strength ETF - CAD
+5.85%2.51% 8 M€
INDEXIQ FACTORS SUSTAINABLE EUROPE EQUITY UCITS ETF - EUR ETF IndexIQ Factors Sustainable Europe Equity UCITS ETF - EUR
+0.28%0.77% 150 M€
DAY HAGAN/NED DAVIS RESEARCH SMART SECTOR INTERNATIONAL ETF - USD ETF Day Hagan/Ned Davis Research Smart Sector International ETF - USD
+2.27%0.31% 32 M€
VANECK WORLD EQUAL WEIGHT SCREENED UCITS ETF - EUR ETF VanEck World Equal Weight Screened UCITS ETF - EUR
+2.05%0.29% 1,212 M€
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS - VANGUARD FTSE ALL-WORLD EX-US ETF ETF Vanguard International Equity Index Funds - Vanguard FTSE All-World ex-US ETF
-1.51%0.28% 33,076 M€
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (UNHEDGED) ETF - JPY ETF Nomura NEXT FUNDS International Equity MSCI-KOKUSAI (Unhedged) ETF - JPY
+0.25%0.23% 399 M€
12

Company Profile

Logo GSK plc
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Employees
66,841
Sector
Pharmaceuticals
More about the company

Income Statement and Estimates

More financial data

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

Quality

Quality

This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

ESG MSCI

ESG MSCI

The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

AA
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
20.66GBP
Average target price
20.32GBP
Spread / Average Target
-1.63%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. ETFs GSK plc
SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener -
United-States
MarketScreener Canada -
Canada

MIDDLE EAST

MarketScreener Saudi Arabia -
Saudi Arabia
MarketScreener UAE Emirates -
United Arab Emirates

EUROPE

Zonebourse -
France
MarketScreener Deutschland -
Deutschland
Zonebourse Suisse -
Suisse
MarketScreener Schweiz -
Schweiz
MarketScreener Italia -
Italia
MarketScreener Österreich -
Österreich
MarketScreener België -
België
MarketScreener Nederland -
Nederland
MarketScreener España -
España
MarketScreener Sverige -
Sverige
MarketScreener UK -
United Kingdom

APAC

MarketScreener Australia -
Australia
MarketScreener India -
India
MarketScreener Hong Kong -
Hong Kong
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition